Ustekinumab trough levels predicting laboratory and endoscopic remission in patients with Crohn’s disease
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-230X
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Ustekinumab trough levels predicting laboratory and endoscopic remission in patients with Crohn’s disease ; volume:22 ; number:1 ; day:21 ; month:4 ; year:2022 ; pages:1-9 ; date:12.2022
BMC gastroenterology ; 22, Heft 1 (21.4.2022), 1-9, 12.2022
- Urheber
-
Hirayama, Hisashi
Morita, Yasuhiro
Imai, Takayuki
Takahashi, Kenichiro
Yoshida, Atsushi
Bamba, Shigeki
Inatomi, Osamu
Andoh, Akira
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12876-022-02271-4
- URN
-
urn:nbn:de:101:1-2022070320372143514839
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:34 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Hirayama, Hisashi
- Morita, Yasuhiro
- Imai, Takayuki
- Takahashi, Kenichiro
- Yoshida, Atsushi
- Bamba, Shigeki
- Inatomi, Osamu
- Andoh, Akira
- SpringerLink (Online service)
Ähnliche Objekte (12)
Ustekinumab Trough Concentrations Are Associated with Biochemical Outcomes in Patients with Crohn’s Disease
Ustekinumab trough concentration affects clinical and endoscopic outcomes in patients with refractory Crohn’s disease: a Chinese real-world study
Posterior Reversible Encephalopathy Syndrome following Ustekinumab Induction for Crohn’s Disease
Elderly-onset Crohn’s disease remarkably responsive to ustekinumab: a case report
Successful Drug Desensitization to Ustekinumab in a Patient with Crohn’s Disease
Ustekinumab inhibits T follicular helper cell differentiation in patients with Crohn’s disease
Cost-effectiveness of ustekinumab in moderate to severe Crohn’s disease in Sweden
Pustular Rash in Crohn’s Patient on Ustekinumab Raises Concern for Drug-Induced Paradoxical Psoriasis
Efficacy, drug sustainability, and safety of ustekinumab treatment in Crohn’s disease patients over three years
Morbus Crohn : akuter Schub und Remission
Ustekinumab bei Colitis ulcerosa und Morbus Crohn : gute anti-entzündliche Wirkung von Ustekinumab in beiden Indikationen
Ustekinumab als Erstlinien-Biologikum in der Therapie des Morbus Crohn : schnelles Ansprechen und langanhaltende Remission bei guter Verträglichkeit
Ustekinumab Trough Concentrations Are Associated with Biochemical Outcomes in Patients with Crohn’s Disease
Ustekinumab trough concentration affects clinical and endoscopic outcomes in patients with refractory Crohn’s disease: a Chinese real-world study
Posterior Reversible Encephalopathy Syndrome following Ustekinumab Induction for Crohn’s Disease
Elderly-onset Crohn’s disease remarkably responsive to ustekinumab: a case report
Successful Drug Desensitization to Ustekinumab in a Patient with Crohn’s Disease
Ustekinumab inhibits T follicular helper cell differentiation in patients with Crohn’s disease
Cost-effectiveness of ustekinumab in moderate to severe Crohn’s disease in Sweden
Pustular Rash in Crohn’s Patient on Ustekinumab Raises Concern for Drug-Induced Paradoxical Psoriasis
Efficacy, drug sustainability, and safety of ustekinumab treatment in Crohn’s disease patients over three years
Morbus Crohn : akuter Schub und Remission
Ustekinumab bei Colitis ulcerosa und Morbus Crohn : gute anti-entzündliche Wirkung von Ustekinumab in beiden Indikationen
Ustekinumab als Erstlinien-Biologikum in der Therapie des Morbus Crohn : schnelles Ansprechen und langanhaltende Remission bei guter Verträglichkeit
Ustekinumab Trough Concentrations Are Associated with Biochemical Outcomes in Patients with Crohn’s Disease
Ustekinumab trough concentration affects clinical and endoscopic outcomes in patients with refractory Crohn’s disease: a Chinese real-world study
Posterior Reversible Encephalopathy Syndrome following Ustekinumab Induction for Crohn’s Disease
Elderly-onset Crohn’s disease remarkably responsive to ustekinumab: a case report
Successful Drug Desensitization to Ustekinumab in a Patient with Crohn’s Disease
Ustekinumab inhibits T follicular helper cell differentiation in patients with Crohn’s disease
Cost-effectiveness of ustekinumab in moderate to severe Crohn’s disease in Sweden
Pustular Rash in Crohn’s Patient on Ustekinumab Raises Concern for Drug-Induced Paradoxical Psoriasis
Efficacy, drug sustainability, and safety of ustekinumab treatment in Crohn’s disease patients over three years
Morbus Crohn : akuter Schub und Remission
Ustekinumab bei Colitis ulcerosa und Morbus Crohn : gute anti-entzündliche Wirkung von Ustekinumab in beiden Indikationen